Shakil Ian's Form 4 filing
Augmedix, Inc. (AUGX) · filed Apr 11, 2024
- Accession no.
- 0001213900-24-032295
- Filed
- Apr 11, 2024
- Trade date
- Apr 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $369.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shakil IanCIK 0001826129 | Director, Officer (CHIEF STRATEGY OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 9, 2024 | Common Stock | MOption exerciseAcquired | +14,356 | $0.64 | +$9,187.84 | 17,356 | Direct | |
| Apr 9, 2024 | Common Stock | MOption exerciseAcquired | +17,186 | $0.86 | +$14,779.96 | 34,542 | Direct | |
| Apr 9, 2024 | Common Stock | SSaleDisposed | −31,542 | $4.14F2 | −$130,583.88 | 3,000 | Direct | |
| Apr 10, 2024 | Common Stock | MOption exerciseAcquired | +36,467 | $0.86 | +$31,361.62 | 39,467 | Direct | |
| Apr 10, 2024 | Common Stock | SSaleDisposed | −36,467 | $3.87F3 | −$141,127.29 | 3,000 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseAcquired | +24,778 | $0.86 | +$21,309.08 | 27,778 | Direct | |
| Apr 11, 2024 | Common Stock | SSaleDisposed | −24,778 | $3.93F4 | −$97,377.54 | 3,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 9, 2024 | Common Stock | MOption exerciseDisposed | −14,356 | $0.00 | $0 | 0 | Direct | |
| Apr 9, 2024 | Common Stock | MOption exerciseDisposed | −17,186 | $0.00 | $0 | 537,238 | Direct | |
| Apr 10, 2024 | Common Stock | MOption exerciseDisposed | −36,467 | $0.00 | $0 | 500,771 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseDisposed | −24,778 | $0.00 | $0 | 475,993 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades ranging from $4.0600 to $4.2400. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades ranging from $3.8000 to $4.0400. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades ranging from $3.8200 to $4.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.